-+ 0.00%
-+ 0.00%
-+ 0.00%

Black Diamond presents Phase 2 silevertinib data in frontline EGFR-mutant NSCLC at ASCO

PUBT·04/21/2026 14:40:19
Listen to the news
Black Diamond presents Phase 2 silevertinib data in frontline EGFR-mutant NSCLC at ASCO
  • Black Diamond Therapeutics scheduled new Phase 2 data for silevertinib (BDTX-1535) in treatment-naïve non-small cell lung cancer patients with non-classical EGFR mutations for an oral presentation at ASCO 2026 on May 30.
  • Presentation will highlight safety profile, with efficacy results intended to support positioning of silevertinib in a frontline setting for this mutation-defined group.
  • Company also plans a Phase 2 poster at ASCO 2026 on May 31 covering previously treated EGFR-mutant non-small cell lung cancer, including non-classical mutations or C797S.
  • Separate trial-in-progress poster on June 1 will outline a randomized Phase 2 study of silevertinib combined with temozolomide in newly diagnosed EGFRvIII-positive glioblastoma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Black Diamond Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604211040PRIMZONEFULLFEED9694025) on April 21, 2026, and is solely responsible for the information contained therein.